Bio­Clin scores a $30M raise from mar­quee in­vestors to fu­el mid-stage work on a new can­cer drug

Bio­Clin Ther­a­peu­tics has round­ed up a fresh load of cash to fu­el some mid-stage tri­al work on its lead — and cur­rent­ly sole — can­cer drug in the clin­ic. The San Ra­mon, CA-based biotech says it gath­ered $30 mil­lion for its Se­ries B, bring­ing the to­tal raised to date to $59 mil­lion.

Bio­Clin is in a Phase Ib/II study of its FGFR3 re­cep­tor drug B-701 com­bined with do­c­etax­el for Stage IV blad­der can­cer. It’s al­so prep­ping a sim­i­lar stage tri­al of the same drug com­bined with Roche’s check­point Tecen­triq (ate­zolizum­ab). This par­tic­u­lar fi­brob­last growth fac­tor re­cep­tor 3 pro­tein has been linked re­peat­ed­ly with tu­mor growth.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER